Johnson & Johnson(JNJ, $142.90) gets rating boost, price target hike from Morgan Stanley
Johnson & Johnson shares rose Tuesday, following a rating upgrade from Morgan Stanley.
Morgan Stanley David Lewis raised his rating on the pharma & medical devices maker's stock to overweight from equal weight.
Lewis also boosted his price target for the shares to $170 a share from $145.
In a note to investors, Lewis called Johnson & Johnson shares "the most under-owned stock in healthcare" . The analyst cited the following factors behind his optimism for JNJ’s attractiveness in 2020: “(1) multiple regulatory actions aimed at controlling pharmaceutical pricing are more reflected, (2) pharma growth like accelerates in 2020, which historically has lifted the multiple and (3) the portfolio is now more balanced with consumer stabilizing and medical devices and diagnostics coming off six consecutive quarters of momentum improvement."
Major growth drivers include the cooling off of pharma headwinds, strong performances by franchises such as Stelara and Darzalex, and pipeline drivers such as Tremfya and Spravato – according to Lewis.
JNJ in +1.54% Uptrend, advancing for three consecutive days on November 20, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JNJ advanced for three days, in of 351 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on JNJ as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on November 12, 2025. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 261 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JNJ broke above its upper Bollinger Band on November 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.173) is normal, around the industry mean (8.811). P/E Ratio (19.620) is within average values for comparable stocks, (23.929). Projected Growth (PEG Ratio) (1.097) is also within normal values, averaging (2.033). Dividend Yield (0.025) settles around the average of (0.026) among similar stocks. P/S Ratio (5.345) is also within normal values, averaging (3.567).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement